Hikma Pharmaceuticals Plc Hikma to launch colchicine 0.6mg capsules (8439B)
January 12 2015 - 2:00AM
UK Regulatory
TIDMHIK
RNS Number : 8439B
Hikma Pharmaceuticals Plc
12 January 2015
PRESS RELEASE
Hikma to launch colchicine 0.6mg capsules
London, 12 January 2015 - Hikma Pharmaceuticals PLC ("Hikma")
(LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing
multinational pharmaceutical group, today notes that Takeda
Pharmaceuticals U.S.A. Inc. ("Takeda") has been unsuccessful in
appealing the decision by the United States District Court for the
District of Delaware to deny Takeda's motion for a preliminary
injunction in relation to the distribution of Hikma's colchicine
0.6mg capsules for the prophylaxis of gout flares in adults. The
injunction, which was granted to Takeda on 9 October 2014, has been
vacated.
Hikma will now prepare to distribute its colchicine, which it
will market under the brand name MITIGARE(TM). Hikma will also be
preparing to launch an authorised generic of MITIGARE(TM),
increasing patient access to this important product.
Said Darwazah, Chairman and CEO of Hikma, said:
"I am very pleased to be launching our colchicine products,
demonstrating our success in developing a more differentiated
product portfolio for the US market."
According to IMS Health, sales of colchicine in the US market
were approximately $688 million for the 12 months ending August
2014.
-- ENDS --
Enquiries
Hikma Pharmaceuticals PLC
Susan Ringdal, VP Corporate Strategy and Director of Investor
Relations +44 (0)20 7399 2760
Lucinda Henderson, Deputy Director of Investor Relations +44
(0)20 7399 2765
FTI Consulting
Ben Atwell/ Matthew Cole/ Julia Phillips +44 (0)20 3727 1000
About Hikma
Hikma Pharmaceuticals PLC is a fast growing multinational group
focused on developing, manufacturing and marketing a broad range of
both branded and non-branded generic and in-licensed products.
Hikma operates through three businesses: "Branded", "Injectables"
and "Generics", based principally in the Middle East and North
Africa ("MENA"), where it is a market leader, the United States and
Europe. In 2013, Hikma achieved revenues of $1,365 million and
profit attributable to shareholders of $212 million.
This information is provided by RNS
The company news service from the London Stock Exchange
END
STRUAUBRVVAAAAR
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024